
On Wednesday, Novavax Inc. (NASDAQ:NVAX) reported second-quarter 2025 sales of $239.24 million, compared to $415 million a year ago, beating the consensus of $156.29 million.
The company completed the transition of Nuvaxovid commercial leadership in the U.S. to Sanofi SA (NASDAQ:SNY) for the 2025-2026 COVID-19 vaccination season.